Special Issue "Real Life Experience of the COVID-19 Vaccine: What Do You Need to Know?"
Deadline for manuscript submissions: 31 January 2024 | Viewed by 18283
It has been two years since the first reports of the SARS-CoV2 pandemic from Wuhan. In that time we have seen 250 million people worldwide infected and, over 5 million deaths and we have learnt that science and a strong public health system can make the difference to our lives.
The current increase of infections due to the spreading of the “omicrom” variant is putting the world under pressure once again. That is why today, in the middle of the fourth wave, it is time to look back and see what has been done in terms of prevention.
The quick development of several types of COVID-19 vaccines, based on mRNA technology and viral vectors, should be considered the biggest goal the scientific community has reached in recent decades. Once the evidence of efficacy and safety was clearly demonstrated in clinical trials, the most important challenge was finding evidence of effectiveness in a wider population. This is what real life studies intended to demonstrate during the mass vaccination campaign. Now, based on almost one year of mass vaccinations and data collection, evidence suggests the vaccines are effective (at least one dose) in preventing infections, hospitalizations, and deaths and in reducing the average hospital stay. On the other hand, unvaccinated individuals are significantly more likely to become infected, need hospitalization and die of COVID-19.
In conclusion, scientific community shares an important social responsibility by analyzing data and communicating the evidence in order to sustain equity in the vaccination campaign.
To achieve a more extensive understanding of recent scientific knowledge and current trends in the SARS-CoV-2 vaccines, this Special Issue is focused on the recent scientific, strategies and results in real life. Based on your extensive knowledge and experience, we invite you to contribute with an original report, original observation or review, to highlight:
- strategies of vaccination;
- safety, immunogenicity and efficacy of SARS-CoV-2 vaccines;
- effectiveness in real-world;
- advances in vaccines development.
Prof. Dr. Vincenzo Baldo
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- COVID-19 vaccines
- vaccine effectiveness